During the period 1970 to 1985, 539 constitutionally tail girls were treated with ethinyloestradiol in varying dosages to reduce final height. They ali had a predicted final height above 181 cm (>+2 5 SD). The girls were all healthy and were treated with three different dosages of ethinyloestradiol. Throughout these 15 years recommended treatment regimens changed, and the treatments described foliowed these guidelines. Girls in group 1 (n=263) were treated with 0-5 mg of ethinyloestradiol, group 2 (n=178) with 0-25 mg, and group 3 (n=98) with 0-1 mg. The total mean (SEM) reduction of final height was 5-9 (0.2), 5-3 (0-1), and 4-4 (0.2) cm when treated with 0-5, 0-25, and 0-1 mg respectively. Group 1 was treated for 2-02 (0.03) years and group 2 and 3 for 1-85 (0.04) and 1-63 (0.05) years respectively. When expressed in relation to the treatment period the reduction of final height was 3-0 (0-1), 3-1 (0-1), and 2-9 (0.2) cm/year of treatment respectively. All the girls were treated with ethinyloestradiol as a daily single dose, while progestogen was given daily the first 10 days of every month.
Tall stature is usually defined as body height of >+2 SD above the population mean. ' In Norway the average final height is 167-3 cm in girls. According to this definition, tall stature in Norway is final height above 178-3 (SD 5-5) cm.2 In 1956 Goldzieher introduced oestrogen as treatment of excessive growth in adolescent girls.3 Since then there have been several different regimens for treating tall girls. Many investigators used conjugated oestrogens, and others used ethinyloestradiol, in varying dosages, usually combined with a progestogen 7-10 days each month to give regular vaginal bleeds. In the 1960s most practitioners used 0-5 mg of ethinyloestradiol, 0 25-0 30 mg in the 1970s, and in the 1980s there have been reports indicating that 0-1 mg is sufficient.' 4'-' However, these studies include a relatively small number of patients (n=5-100).
Arterial thromboembolic complications and possible carcinogenic effects of the long term oestrogen treatment by contraceptive pills make it important to find the lowest dosage of oestrogen giving a satisfactory reduction of final height. We have compared the growth reducing effect of three different dosages in 539 tall girls, demonstrating that low dose (0-1 mg) treatment is as effective as high dose (0-5 mg). Furthermore, we have studied the optimum age for start of treatment in relation to the treatment period needed. Height reduction in 539 tall girls treated with three different dosages ofethinyloestradiol In the group with bone age 12-5-13-0 years the height reduction was significantly different between the three dosage regimens (p<001), but there was no significant difference between the groups in 'corrected' reduction.
In the most mature group (bone age ¢ 13-0) there was no significant difference between the three dosage regimens in either total or 'corrected' height reduction (fig 1) .
In none of these groups did the girls develop side effects that lasted more than three months. The main side effect was nausea. Some had dysmenorrhea, but usually this disappeared after some months. A detailed report on side effects was published earlier and showed fewer problems with low dose treatment.'3 The girls were not followed up systematically after completion of treatment. Some have become mothers and, as far as we know, none has developed infertility problems or malignant disease. This is too early to ascertain breast and genital carcinomas. No girl has developed prolactinoma to our knowledge. final height was 4-6 cm. The reduction in the youngest group with bone age 12-1-13 years was 5 8 cm while the reduction in the group with bone age 13 1-14 years was 4 0 cm. The group with bone age 14-1-15 had a reduction of 4-5 cm. The differences were not significant, but they gave an indication that the reduction of final height was less when treatment was started after bone age of about 13 years. This corresponded to the study of Kuhn et compared.9 They showed that the reduction of final height was 4-9 cm in the low dose (0 1 mgof ethinyloestradiol daily) compared with 5-1 cm in the high dose (0 3-0 5 mg daily) regimen. This difference was not significant. The final height was reduced when treatment was started at a bone age less than 13 years. The groups were small (n=44 and n= 38 respectively) and they were treated at two different centres.
These results are all in accordance with ours. There is no statistical difference in growth inhibiting effect between the three dosages when the duration of treatment and bone age at start of treatment are taken into account. Using 0 1 mg of ethinyloestradiol is as efficient as 0 5 mg. It has been suggested that in girls with more advanced pubertal development, a higher dosage of oestrogen should be more effective. 12
In girls with bone age ¢ 13-0 years the total height reduction was 6 mm less when given 0-1 mg daily compared with the 0 5 mg regimen, but when correlated to the treatment period there was no difference. This does not justify a higher dosage (0-5 mg) which would, with a treatment period of 2-02 years, be equivalent to a total dose of about 36 years' use of a low dose (35 Rig) contraceptive pill compared with six years when treated with 01 mg ethinyloestradiol daily for 1 63 years. Thus irrespective of the bone age when starting treatment, low dose oestrogen treatment is as effective as high dose treatment. Furthermore early treatment, starting before bone age 12-5 years, is most effective. After bone age 13 years less benefit is obtained. There is a definite decrease in growth reducing effect when bone age is ¢ 13 0 years. The difference in reduction of final height between the two groups with bone age less than 13 years is clinically not significant, although it is statistically different due to the large number of patients. This is the first report including more than 500 tall girls from only one centre examined and treated by the same investigator. This minimises the variations observed in height measurements, bone age estimations, height predictions, and indications of treatment.
From our study we conclude that starting treatment at a bone age of about 120-12-5 years, using 0-1 mg of ethinyloestradiol daily for about two years, combined with 5 mg medroxyprogesteroneacetate daily for the first 10 days of every month, will give satisfactory results with an average reduction of final height of 5-2 cm. Because of the possibility of nausea, with or without vomiting, we recommend starting treatment on a Friday to minimise loss of schooling. Such side effects are most frequent with higher dosages. As Trygstad reported in 1986, there has not been a problem of major side effects.13
Whether even lower dosages (for example 35 ,tg daily) are equally effective should be assessed in a prospective clinical trial.
